Drug Discovery & Development
Preclinical data on long-acting tuberculosis drug raises hopes for simplified treatment
A long-acting injectable formulation of rifabutin has delivered high plasma concentrations for 16 weeks in mice, resulting in the prevention of tuberculosis and the clearing of the pathogen from the lungs. Read More
Production technique clears barrier to widespread study of intestinal organoids
The aggregation of cells removes variability from the production of small intestinal organoids, clearing a major hurdle to the widespread use of the technologies as a research tool for studying the digestive system, according to a paper published July 28 in Stem Cell Reports. Read More
Cardiac mouse model shows role white blood cells play in arrhythmia
Feeding mice a diet lacking in potassium induces ventricular tachycardia, a rapid heartbeat, enabling researchers to study how different white blood cell subclasses influence heart rhythms. Read More
Manufacturing partnerships support high quality cell therapies
Chimeric Therapeutics, Ncardia, and Novartis are some of the companies that have decided to partner to make complex manufacturing processes more efficient for novel therapies, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard. Read More
Nivolumab/chemo combo will change lung cancer care
A new study that pairs neoadjuvant nivolumab with chemotherapy for patients with nonsmall cell lung cancer has the potential to revolutionize treatment, according to one expert. The research was presented April 11 at the American Association for Cancer Research 2022 meeting and published simultaneously in the New England Journal of Medicine. Read More
CAR T-cells show preliminary efficacy, safety as solid-tumor treatment
Researchers presented phase I/II preliminary clinical trial data demonstrating the safety and efficacy of a new CAR T-cell therapy that can be used as either a monotherapy or a combination therapy to treat Claudin 6-positive solid tumors. The findings were presented at the American Association for Cancer Research Annual Meeting 2022 in New Orleans. Read More
How diversity, inclusion help one company turn sci-fi into sci-fact
Juliana Blum, PhD, co-founder and executive vice president of corporate development at Humacyte, spoke with ScienceBoard about diversity and inclusion in the life sciences, especially about being a woman in science. Read More
Combined imaging approach gives detailed picture of blood vessels
Mapping out the intricate network of blood vessels in tissues can help researchers to better understand the changes in diseases like dementia or cancer. However, techniques to image the vasculature are individually limited and difficult to combine. Now, a new easy-to-use system, described in a paper published February 10 in the journal Nature Methods, can combine multiple imaging techniques to provide more detailed information at a range of scales. Read More
Funding for cell and gene therapies exceeded $70B in 2021
Total funding from all sources for cell and gene therapy companies totaled $70.8 billion last year, according to the recent “Cell and Gene Therapy Deals: Financings, Partnering, M&A, Technology Transfers, IPOs, and Other Developments” report published by Kalorama Information, a sister company of ScienceBoard. Read More
Scientists improve ADC development with mix of experimental, computational tools
BOSTON -- Greg Thurber, PhD, professor at the University of Michigan explained how his lab is jointly using both experimental animal models and computational models to improve the overall speed and efficiency of drug development of antibody-drug conjugates (ADCs) to get more of the agents on the market. Thurber presented in a scientific session at the Society for Laboratory Automation and Screening (SLAS) 2022 International Conference and Expo. Read More
Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter